Next 10 |
MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, disclosed the final figures resulting from its partnership with a biopharmaceutical company focused on infectious disease prevention research. Science 37 contributed ...
RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets. Leveraging its proprietary ...
RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Science 37, Inc., please note that the first sentence of the second paragraph has been revised. The corrected release follows: Science 37 Holdings, Inc. , a lea...
RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. , a leader in enhancing patient access to clinical trials, announced the final enrollment figures from its 20-month engagement with a clinical-stage drug development company advancing novel small mol...
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation. The nearly two-week review included, but was not limited to, the Science 37 Metasite&...
Science 37’s Patient Recruitment Recognized in Prestigious International Annual Awards Program for Standout Digital Health & Medical Technology Products and Companies RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. , today announ...
RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3...
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., the clinical research industry’s leading Metasite TM , today announced the launch of a stand-alone Patient Recruitment Solution to deliver patients to sites that are eligible, medically reviewed...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
News, Short Squeeze, Breakout and More Instantly...
Science 37 Holdings Inc. Company Name:
SNCE Stock Symbol:
NASDAQ Market:
Science 37 Holdings Inc. Website:
MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, disclosed the final figures resulting from its partnership with a biopharmaceutical company focused on infectious disease prevention research. Science 37 contributed ...
RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets. Leveraging its proprietary ...
RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Science 37, Inc., please note that the first sentence of the second paragraph has been revised. The corrected release follows: Science 37 Holdings, Inc. , a lea...